Literature DB >> 32652693

Cardiac surgery and COVID-19.

Viroj Wiwanitkit1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32652693      PMCID: PMC7405218          DOI: 10.1111/jocs.14826

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


× No keyword cloud information.
Dear Editor, I would like to comment on “Cardiac surgery in patients with confirmed COVID‐19 infection: early experience.” Surgery is usually considered a risky procedure for COVID‐19 contact during this pandemic. In general, elective surgery is usually postponed but necessary/emergency surgery may be still indicated. Good prevention is important and the operation for COVID‐19 patients does not mean there will be further disease spread. The operation in asymptomatic COVID‐19 patients has been reported and there is no further transmission to anyone even though the diagnosis of COVID‐19 is made after the operation. The experience of Hussain et al on cardiac surgery on patients with COVID‐19 confirms that good planning and management are important for these operations. Furthermore, the surgeon is assured that COVID‐19 patients who require cardiac surgery during this outbreak is feasible and can be done safely and effectively. Nevertheless, interesting data that Hussain et al may have omitted is to report on the preparation of the patient before and after surgery, with isolation/surveillance procedures. For the management of a COVID‐19 patient, the focus should be not only during the operation phase but also pre‐and postsurgery.

CONFLICT OF INTEREST

The author declares that there is no conflict of interest.
  2 in total

1.  Carpal Fracture and COVID-19 Infection: Observation from Thailand.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Indian J Orthop       Date:  2020-04-21       Impact factor: 1.251

2.  Cardiac surgery in patients with confirmed COVID-19 infection: Early experience.

Authors:  Azhar Hussain; Habib Khan; Ana Lopez-Marco; Neil Roberts; Aung Oo
Journal:  J Card Surg       Date:  2020-06       Impact factor: 1.620

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.